CHEMOTHERAPY OF ADVANCED GASTRIC CANCER

Publisher Website
Google Scholar
Abstract
Patients (28) with inoperable or metastatic gastric cancer were treated with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-C (FAM). Patients (21) had measurable disease parameters and 57% of these experienced a major regression of disease following chemotherapy. The median survival of the responding patients was 13.2 mo. compared with 6.8 mo. in the group who did not achieve a major response. These results demonstrate the sensitivity of gastric carcinoma to this drug combination.